No data available for drug.
Dosing & Uses
Drug Interaction
Adverse Reaction
Actions and Spectrum
Black Box Warning
Contraindication / Caution
Pregnancy / Lactation
Pharmacology
Administration
Patient Information Leaflet
DRUG INTERACTION
No drug interaction found for simvastatin and .
Contraindicated
amlodipine
may enhance the serum concentration of amlodipine
daptomycin
may increase the toxic effects of antibiotics
lanthanum carbonate
may diminish the serum concentration when combined with HMG-CoA reductase inhibitors (statins)
fostemsavir
may enhance the serum concentration of fostemsavir
amlodipine
may enhance the concentration of serum when combined with simvastatin
niacin
niacin: they may increase the myopathic effect of simvastatin
Serious Use Alternative
lenacapavir
CYP3A4 inhibitors increase the concentration of active metabolites of simvastatin in the serum
curcumin
CYP3A4 inhibitors increase the concentration of active metabolites of simvastatin in the serum
glecaprevir
CYP3A4 inhibitors increase the concentration of active metabolites of simvastatin in the serum
caspofungin
CYP3A4 inhibitors increase the concentration of active metabolites of simvastatin in the serum
abiraterone
CYP3A4 inhibitors increase the concentration of active metabolites of simvastatin in the serum
griseofulvin
It may diminish the effect when combined with griseofulvin by CYP3A4 metabolism
miconazole vaginal
It may enhance the effect when combined with miconazole vaginal by affecting CYP3A4 metabolism
nafcillin
nafcillin will decrease the effect of action of simvastatin by affecting enzyme CYP3A4 metabolism.
ivosidenib
when both drugs are combined, there may be a decreased effect of simvastatin by affecting hepatic or intestinal enzyme cyp3a4 metabolism
daptomycin
may increase the toxic effects of antibiotics
Monitor Closely
acenocoumarol
may enhance the anticoagulant effect of Vitamin K Antagonists
fluindione
may enhance the anticoagulant effect of Vitamin K Antagonists
phenindione
may enhance the anticoagulant effect of Vitamin K Antagonists
phylloquinone
may enhance the anticoagulant effect of Vitamin K Antagonists
warfarin
may enhance the anticoagulant effect of Vitamin K Antagonists
maralixibat
may enhance the concentration of serum when combined with simvastatin
cholic acid
It may enhance toxicity when combined with cholic acid by diminishing the elimination
lenacapavir
simvastatin: they may enhance serum concentrations of CYP3A Inhibitors
abiraterone
simvastatin: they may enhance serum concentrations of CYP3A Inhibitors
mibefradil
simvastatin: they may enhance serum concentrations of CYP3A Inhibitors
citalopram
simvastatin: they may enhance serum concentrations of CYP3A Inhibitors
efavirenz
simvastatin: they may enhance serum concentrations of CYP3A Inhibitors
etoposide
when both drugs are combined, there may be an increased level of serum concentration of etoposide
vinblastine
when both drugs are combined, there may be an increased level of serum concentration of vinblastine
lorlatinib
the effect of simvastatin is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
phenindione
may increase the anticoagulant effect of vitamin K antagonist
phylloquinone
may increase the anticoagulant effect of vitamin K antagonist
warfarin
may increase the anticoagulant effect of vitamin K antagonist
acenocoumarol
may increase the anticoagulant effect of vitamin K antagonist
fluindione
may increase the anticoagulant effect of vitamin K antagonist
voxelotor
may enhance the serum concentration of CYP3A4 Inhibitors
chlorzoxazone
may increase the CNS depressant effect of CNS Depressants
raltegravir
may increase the myopathic effect of HMG-CoA Reductase Inhibitors
efavirenz
may decrease the serum concentration
Minor
telmisartan
may increase the toxicity of each other when combined
No data available for drug.
Dosing & Uses
Adult
Pediatric
Geriatric
Drug Interaction
DRUG INTERACTION
simvastatin
&
No Drug Intearction Found. for simvastatin and .
Contraindicated
amlodipine
may enhance the serum concentration of amlodipine
daptomycin
may increase the toxic effects of antibiotics
lanthanum carbonate
may diminish the serum concentration when combined with HMG-CoA reductase inhibitors (statins)
fostemsavir
may enhance the serum concentration of fostemsavir
amlodipine
may enhance the concentration of serum when combined with simvastatin
niacin
niacin: they may increase the myopathic effect of simvastatin
Serious Use Alternative
lenacapavir
CYP3A4 inhibitors increase the concentration of active metabolites of simvastatin in the serum
curcumin
CYP3A4 inhibitors increase the concentration of active metabolites of simvastatin in the serum
glecaprevir
CYP3A4 inhibitors increase the concentration of active metabolites of simvastatin in the serum
caspofungin
CYP3A4 inhibitors increase the concentration of active metabolites of simvastatin in the serum
abiraterone
CYP3A4 inhibitors increase the concentration of active metabolites of simvastatin in the serum
griseofulvin
It may diminish the effect when combined with griseofulvin by CYP3A4 metabolism
miconazole vaginal
It may enhance the effect when combined with miconazole vaginal by affecting CYP3A4 metabolism
nafcillin
nafcillin will decrease the effect of action of simvastatin by affecting enzyme CYP3A4 metabolism.
ivosidenib
when both drugs are combined, there may be a decreased effect of simvastatin by affecting hepatic or intestinal enzyme cyp3a4 metabolism
daptomycin
may increase the toxic effects of antibiotics
Monitor Closely
acenocoumarol
may enhance the anticoagulant effect of Vitamin K Antagonists
fluindione
may enhance the anticoagulant effect of Vitamin K Antagonists
phenindione
may enhance the anticoagulant effect of Vitamin K Antagonists
phylloquinone
may enhance the anticoagulant effect of Vitamin K Antagonists
warfarin
may enhance the anticoagulant effect of Vitamin K Antagonists
maralixibat
may enhance the concentration of serum when combined with simvastatin
cholic acid
It may enhance toxicity when combined with cholic acid by diminishing the elimination
lenacapavir
simvastatin: they may enhance serum concentrations of CYP3A Inhibitors
abiraterone
simvastatin: they may enhance serum concentrations of CYP3A Inhibitors
mibefradil
simvastatin: they may enhance serum concentrations of CYP3A Inhibitors
citalopram
simvastatin: they may enhance serum concentrations of CYP3A Inhibitors
efavirenz
simvastatin: they may enhance serum concentrations of CYP3A Inhibitors
etoposide
when both drugs are combined, there may be an increased level of serum concentration of etoposide
vinblastine
when both drugs are combined, there may be an increased level of serum concentration of vinblastine
lorlatinib
the effect of simvastatin is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
phenindione
may increase the anticoagulant effect of vitamin K antagonist
phylloquinone
may increase the anticoagulant effect of vitamin K antagonist
warfarin
may increase the anticoagulant effect of vitamin K antagonist
acenocoumarol
may increase the anticoagulant effect of vitamin K antagonist
fluindione
may increase the anticoagulant effect of vitamin K antagonist
voxelotor
may enhance the serum concentration of CYP3A4 Inhibitors
chlorzoxazone
may increase the CNS depressant effect of CNS Depressants
raltegravir
may increase the myopathic effect of HMG-CoA Reductase Inhibitors
efavirenz
may decrease the serum concentration
Minor
telmisartan
may increase the toxicity of each other when combined
Actions and Spectrum
Adverse Reaction
Black Box Warning
Contraindication / Caution
Pregnancy / Lactation
Pharmacology
Administration
Patient Information Leaflet
medtigo
Action and Spectrum
Drug Interaction
Adverse Reaction
Black Box Warning
Contraindication / Caution
Pregnancy / Lactation
Pharmacology
Adminstartion
Patient Information Leaflet